Giant Cell Arteritis: Diagnosis and Treatment
Diagnostic Criteria
Giant cell arteritis (GCA) should be diagnosed when a patient ≥50 years old presents with a cumulative score of ≥6 points using the 2022 ACR/EULAR classification criteria, which achieved 87% sensitivity and 95% specificity in validation studies. 1
Absolute Requirement
- Age ≥50 years at diagnosis is mandatory for classification as GCA 1
Weighted Diagnostic Criteria (Points-Based System)
High-Value Criteria (+5 points each):
- Positive temporal artery biopsy showing necrotizing arteritis with mononuclear cell infiltrates or granulomatous inflammation with multinucleated giant cells 2, 1
- Temporal artery "halo sign" on ultrasound (hypoechoic wall thickening) 1
Moderate-Value Criteria (+3 points each):
Standard-Value Criteria (+2 points each):
- New-onset localized headache 1
- Scalp tenderness 1
- Jaw or tongue claudication 1
- Morning stiffness in shoulders or neck 1
- Temporal artery abnormality on physical examination (tenderness or decreased pulse) 1
- Bilateral axillary involvement on imaging 1
- FDG-PET activity throughout the aorta 1
Diagnostic Imaging Modalities
Temporal artery ultrasound is the preferred first-line imaging when performed at centers with expertise, demonstrating 78% sensitivity and 79% specificity for detecting the characteristic "halo sign" of vessel wall inflammation 3
FDG-PET/CT achieves 71% sensitivity and 91% specificity using state-of-the-art time-of-flight technique, and is particularly valuable for detecting large-vessel involvement 3
Critical timing caveat: Both ultrasound and PET/CT sensitivities decrease substantially after glucocorticoid administration, so imaging should ideally be performed before treatment initiation 3
Temporal artery biopsy remains the gold standard confirmatory test, though it misses approximately 15% of cases due to the focal and segmental nature of vascular inflammation 2
Treatment Protocol
Initial Therapy
Start high-dose oral prednisone 40–60 mg daily immediately upon clinical suspicion of GCA, even before diagnostic confirmation, to prevent irreversible ischemic complications including blindness and stroke. 2, 4
- For uncomplicated cranial GCA without visual symptoms: prednisone 40–60 mg/day 2
- The European League Against Rheumatism emphasizes initiating treatment urgently when clinical suspicion is high, given the catastrophic risk of permanent vision loss 5
Adjunctive Antiplatelet Therapy
Add low-dose aspirin 75–100 mg daily at diagnosis, as this significantly reduces the rate of vision loss and stroke during the disease course 2
Glucocorticoid-Sparing Therapy
Tocilizumab (IL-6 Receptor Blockade)
Tocilizumab is the only proven glucocorticoid-sparing agent for GCA and should be initiated early in the treatment course to reduce cumulative steroid exposure and increase sustained remission rates. 3, 4, 6
- Weekly tocilizumab achieved sustained glucocorticoid-free remission in 56% of patients compared with only 18% receiving a 52-week prednisone taper alone 3
- Tocilizumab markedly reduces cumulative glucocorticoid dose and associated adverse effects 3, 4
Important monitoring caveat: Traditional acute-phase reactants (ESR, CRP) become unreliable for disease activity assessment in patients receiving IL-6 receptor blockade, necessitating clinical assessment and imaging for flare detection 3
Other Biologic Agents
- Abatacept and ustekinumab have shown promise in smaller studies but lack the robust evidence base of tocilizumab 6
- These agents may be considered when tocilizumab is contraindicated, ineffective, or not tolerated 6
Disease Monitoring and Relapse Detection
Relapses are common despite glucocorticoid therapy, making long-term surveillance essential 4
- Monitor for recurrence of cranial symptoms (headache, jaw claudication, visual changes) and systemic symptoms (fever, weight loss, fatigue) at each visit 7
- Serial imaging with ultrasound, MRI, or PET/CT may be needed to detect subclinical large-vessel disease progression 8, 6
- In patients not receiving tocilizumab, ESR and CRP remain useful markers, though they are imperfect indicators of disease activity 3
Large-Vessel Complications
GCA patients face markedly increased risk of aortic aneurysms and aortic dissection, raising important questions about screening protocols 8
- Involvement of the aorta and its proximal branches is far more common than historically appreciated, detected by modern imaging modalities 8
- Whether patients with large-vessel involvement require more aggressive or prolonged immunosuppression remains an area of active investigation 8, 4
- Surgical intervention may be indicated for refractory ischemia or aortic complications, though outcomes data are limited 4
Key Clinical Pitfalls to Avoid
- Do not delay glucocorticoid initiation while awaiting biopsy or imaging results when clinical suspicion is high—irreversible blindness can occur within hours to days 7, 2
- Do not rely solely on ESR/CRP for diagnosis or monitoring, as approximately 15% of biopsy-proven GCA cases have normal inflammatory markers 2
- Do not perform imaging after starting glucocorticoids if avoidable, as sensitivity drops significantly within days of treatment 3
- Do not assume GCA is purely a cranial disease—screen for large-vessel involvement given the high prevalence of aortitis and risk of aneurysm formation 8, 4
Multidisciplinary Management
Rheumatologists should lead GCA management, with expertise in immunosuppression, biologic therapies, and long-term glucocorticoid tapering 9